These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 6805238)

  • 1. [Efficacy of a daily dosage of dapsone combined with a single dose of rifampicin. Clinical, bacteriological and histopathological evaluation].
    Le KD; Nguyen N; Nguyen VM
    Acta Leprol; 1981; 85():75-82. PubMed ID: 6805238
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
    Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
    Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of adding rimactane (rifampicin) 450 milligrams daily or 1200 milligrams once monthly in a single dose to dapsone 50 milligrams daily in patients with lepromatous leprosy.
    Languillon J; Yawalkar SJ; McDougall AC
    Int J Lepr Other Mycobact Dis; 1979 Mar; 47(1):37-43. PubMed ID: 376454
    [No Abstract]   [Full Text] [Related]  

  • 4. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled comparison of therapeutic effects of DDS in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy.
    Ghosh S; McDougall AC; Hazra SK; Yawalkar SJ
    Indian J Dermatol; 1981 Oct; 26(4):1-6. PubMed ID: 6754585
    [No Abstract]   [Full Text] [Related]  

  • 6. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.
    Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up study of pauci-bacillary leprosy on-multi-drug regimen.
    Ramanan R; Manglani PR; Ghorpade A; Bhagoliwal SK
    Indian J Lepr; 1987; 59(1):50-3. PubMed ID: 3611861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dynamics of establishing resistance of M. leprae to dapsone and rifampicin in Martinique].
    Constant-Desportes-Relouzat M; Grosset J; Guelpalauras CC; Salvini B; Cales-Quist D
    Acta Leprol; 1986; 4(3):293-300. PubMed ID: 3551468
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of single dose (1500 mg) rifampicin on infectivity of patients with lepromatous leprosy.
    Girdhar BK; Sreevatsa ; Desikan KV
    Lepr India; 1980 Jul; 52(3):359-65. PubMed ID: 7206633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short term combination therapy for paucibacillary leprosy--histological evaluation & follow-up study.
    Kumar B; Kaur S; Kaur I
    Indian J Lepr; 1987; 59(1):54-62. PubMed ID: 3302061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone.
    Gelber RH; Humphres RC; Fieldsteel AH
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New WHO recommendations for the treatment of leprosy].
    Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
    [No Abstract]   [Full Text] [Related]  

  • 14. 'Pulsed' rifampicin therapy in leprosy. A clinical study.
    Girdhar BK; Desikan KV
    Lepr India; 1979 Oct; 51(4):475-80. PubMed ID: 392192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampin.
    Katoch K; Ramanathan U; Natrajan M; Bagga AK; Bhatia AS; Saxena RK; Ramu G
    Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):458-64. PubMed ID: 2746075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic trials with different regimens containing rifampicin in paucibacillary type of leprosy cases--a preliminary report.
    Katoch K; Ramu G; Ramanathan U
    Indian J Lepr; 1985; 57(3):499-506. PubMed ID: 3831087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introductory rifampicin therapy in lepromatous leprosy: a six month follow-up study.
    Girdhar BK; Ramu G; Sreevatsa ; Desikan KV
    Lepr India; 1978 Jul; 50(3):363-70. PubMed ID: 359925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance and multi-drug therapy in leprosy.
    Chatterjee BR
    Indian J Lepr; 1989 Jul; 61(3):328-32. PubMed ID: 2768881
    [No Abstract]   [Full Text] [Related]  

  • 20. A clinico-pathological study of multidrug regimen in paucibacillary leprosy.
    Kar PK; Jha PK; Panayach JS; Snehi PS
    Indian J Lepr; 1988 Apr; 60(2):235-41. PubMed ID: 3192972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.